Anti-EGFR-Based Therapy in Recurrent or Metastatic HNSCC - What Difference Does it Make?

Area of Science:

• Oncology
• Clinical Research
• Head and Neck Cancer

Background:

• Recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) presents a significant clinical challenge.
• Palliative first-line therapy is a common treatment approach for patients with R/M HNSCC.
• The utilization of targeted therapies like cetuximab has evolved over time.

Purpose of the Study:

• To evaluate changes in overall survival for patients with R/M HNSCC.
• To assess the impact of cetuximab utilization on survival outcomes in a real-world setting.
• To analyze survival trends before and after the broad adoption of cetuximab.

Main Methods:

• Retrospective analysis of R/M HNSCC patients receiving palliative first-line therapy.
• Inclusion criteria: Patients treated at Hannover Medical School from October 2005 to December 2016.
• Comparison of survival data between two treatment periods: 10/2005-12/2008 and 01/2009-12/2016.

Main Results:

• Overall survival did not demonstrate significant improvement across the entire study period.
• Subgroup analysis revealed a significant improvement in overall survival for patients receiving cetuximab at any point compared to those who never received it (11.3 vs. 6.3 months).
• Hazard ratio (HR) for cetuximab use was 0.55 (95% CI: 0.4-0.8, p=0.04), indicating a survival benefit.

Conclusions:

• While overall survival trends did not change significantly, cetuximab demonstrated a positive impact on survival in a real-world R/M HNSCC population.
• The findings support the continued application of cetuximab as a therapeutic option for R/M HNSCC.
• Real-world data provides valuable insights into the effectiveness of targeted therapies in specific patient subgroups.